company background image
A006280 logo

GC Biopharma KOSE:A006280 Stock Report

Last Price

₩109.60k

Market Cap

₩1.3t

7D

-2.2%

1Y

-15.3%

Updated

17 Apr, 2024

Data

Company Financials +

A006280 Stock Overview

GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally.

A006280 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth3/6
Past Performance0/6
Financial Health3/6
Dividends1/6

GC Biopharma Corp. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for GC Biopharma
Historical stock prices
Current Share Price₩109,600.00
52 Week High₩134,300.00
52 Week Low₩93,000.00
Beta1.09
1 Month Change-9.35%
3 Month Change0.46%
1 Year Change-15.30%
3 Year Change-71.90%
5 Year Change-23.36%
Change since IPO-63.17%

Recent News & Updates

GC Biopharma Corp.'s (KRX:006280) Business And Shares Still Trailing The Industry

Mar 08
GC Biopharma Corp.'s (KRX:006280) Business And Shares Still Trailing The Industry

Recent updates

GC Biopharma Corp.'s (KRX:006280) Business And Shares Still Trailing The Industry

Mar 08
GC Biopharma Corp.'s (KRX:006280) Business And Shares Still Trailing The Industry

We Think Green Cross (KRX:006280) Can Stay On Top Of Its Debt

May 02
We Think Green Cross (KRX:006280) Can Stay On Top Of Its Debt

Are Green Cross Corporation's (KRX:006280) Mixed Financials Driving The Negative Sentiment?

Mar 10
Are Green Cross Corporation's (KRX:006280) Mixed Financials Driving The Negative Sentiment?

Shareholders Are Thrilled That The Green Cross (KRX:006280) Share Price Increased 268%

Feb 18
Shareholders Are Thrilled That The Green Cross (KRX:006280) Share Price Increased 268%

Green Cross (KRX:006280) Has A Somewhat Strained Balance Sheet

Jan 31
Green Cross (KRX:006280) Has A Somewhat Strained Balance Sheet

Calculating The Intrinsic Value Of Green Cross Corporation (KRX:006280)

Jan 14
Calculating The Intrinsic Value Of Green Cross Corporation (KRX:006280)

What You Need To Know About Green Cross Corporation's (KRX:006280) Investor Composition

Dec 27
What You Need To Know About Green Cross Corporation's (KRX:006280) Investor Composition

Green Cross Corporation's (KRX:006280) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Dec 09
Green Cross Corporation's (KRX:006280) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Does Green Cross's (KRX:006280) Statutory Profit Adequately Reflect Its Underlying Profit?

Nov 21
Does Green Cross's (KRX:006280) Statutory Profit Adequately Reflect Its Underlying Profit?

Shareholder Returns

A006280KR BiotechsKR Market
7D-2.2%-3.2%-3.0%
1Y-15.3%-2.6%0.6%

Return vs Industry: A006280 underperformed the KR Biotechs industry which returned -2.6% over the past year.

Return vs Market: A006280 underperformed the KR Market which returned 0.6% over the past year.

Price Volatility

Is A006280's price volatile compared to industry and market?
A006280 volatility
A006280 Average Weekly Movement2.9%
Biotechs Industry Average Movement8.0%
Market Average Movement5.2%
10% most volatile stocks in KR Market12.0%
10% least volatile stocks in KR Market2.4%

Stable Share Price: A006280 has not had significant price volatility in the past 3 months.

Volatility Over Time: A006280's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19672,098Il-Sup Huhwww.globalgreencross.com

GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-GCC injection (inj.) for hypoalbuminemia and shock in acute hemorrhage, as well as low synthesis of albumin; Antithrombin-III (AT-III) inj.

GC Biopharma Corp. Fundamentals Summary

How do GC Biopharma's earnings and revenue compare to its market cap?
A006280 fundamental statistics
Market cap₩1.26t
Earnings (TTM)-₩26.63b
Revenue (TTM)₩1.63t

0.8x

P/S Ratio

-47.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A006280 income statement (TTM)
Revenue₩1.63t
Cost of Revenue₩1.14t
Gross Profit₩483.33b
Other Expenses₩509.96b
Earnings-₩26.63b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.33k
Gross Margin29.71%
Net Profit Margin-1.64%
Debt/Equity Ratio39.2%

How did A006280 perform over the long term?

See historical performance and comparison

Dividends

1.4%

Current Dividend Yield

500%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.